Lytica Therapeutics has filed a notice of an exempt offering of securities to raise $4,065,000.00 in New Debt Financing.
According to filings with the U.S. Securities and Exchange Commission, Lytica Therapeutics is raising up to $4,065,000.00 in new funding. Sources indicate that as part of senior management President, Rida Mourtada played a key role in securing the recent investment.
About Lytica Therapeutics
Lytica Therapeutics, Inc. is a biotechnology company focused on developing novel peptide therapeutics. Traditional antibody-drug conjugates combine two technologies into one: targeted antibodies and cytotoxic payloads. At Lytica, we’re challenging that definition by building unique conjugates that imbue antibodies with new therapeutic properties. Our stapled peptide platform enables rapid exploration of ADC combinations. We’re leveraging our expertise in stapled peptides to push ADC technology forward.
To learn more about Lytica Therapeutics, visit http://www.lyticatx.com/
Contact:
Rida Mourtada, President
617-475-7374
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.